First Patient Enrolled and Dosed in Novan’s SB206 Phase 3 Molluscum Program

MORRISVILLE, N.C., June 04, 2019 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that the first patient has been dosed in the Company’s “B-SIMPLE” ( Berdazimer Sodium In Molluscum Patients with Lesions) Phase 3 program. The study is designed to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum contagiosum.